Letters to the EditorInterferon and hepatocellular carcinoma
References (1)
Cited by (14)
Interferon for preventing and treating hepatocellular carcinoma associated with the hepatitis B and C viruses
2003, Digestive and Liver DiseaseCost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C
2000, American Journal of MedicineCitation Excerpt :These patients, however, had become viral-negative during their first course of treatment, whereas the trial of combination therapy (6) included biochemical relapsers who did not necessarily clear hepatitis C virus with their first course of interferon, thus making direct comparisons of these two trials difficult (31). We used surrogate markers (virologic response) and assumed that virologic responders have a more benign prognosis than nonresponders (32), although not all investigators (33–37) share this assumption. Moreover, some studies have not shown that responders have a better outcome (38–40).
Treatment of patients with chronic hepatitis C and cirrhosis
1999, Journal of Hepatology, SupplementInterferon for interferon nonresponding and relapsing patients with chronic hepatitis C
2013, Cochrane Database of Systematic Reviews
Copyright © 1996 Published by Elsevier Ltd.